Prostatype Genomics AB announces outcome of TO 2
On March 30, 2023, the exercise period for Prostatype Genomics AB's ("Prostatype Genomics" or the "Company") warrants of series TO 2 ended. A total of 2,622 warrants of series TO 2 have been exercised, corresponding to SEK 7,603.80.During the period from the 9[th] of March until the 30[th] of March 2023, holders of warrants of series TO 2 had the right to subscribe for shares with the support of warrants. One (1) warrant of series TO 2 gave the holder the right to subscribe for one (1) new share in Prostatype Genomics at a subscription price set at SEK 2.90. A total of 2,622 warrants of